Levetiracetam Tablet
Product Images NDC 71335-2275

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 71335-2275). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713352275)

Levetiracetam Tablets USP 250 mg oral tablets, NDC 71335-2275-1, repackaged by Bryant Ranch Prepack, containing 60 tablets per container. Label includes storage instructions, child-resistant warning, and manufacturer Zhejiang Huahai Pharmaceutical Co. Ltd. Barcode and lot, expiration, and serial numbers are also visible.*

FDA Label Image

Structure Formula (Levetiracetam Tablets 1)

Chemical structure of levetiracetam, showing the molecular arrangement including a pyrrolidone ring and associated functional groups.*

FDA Label Image

Figure 1 (Levetiracetam Tablets 2)

A bar chart comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The chart shows markedly higher patient percentages in the Levetiracetam groups compared to placebo, with values above 30% for Levetiracetam doses and about 7% for placebo.*

FDA Label Image

Figure2 (Levetiracetam Tablets 3)

A vertical bar chart comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The chart shows increasing patient percentages from 6.3% for Placebo, 20.8% for Levetiracetam 1000 mg/day, to 35.2% for Levetiracetam 2000 mg/day, with each bar labeled with the corresponding patient count (N).*

FDA Label Image

Figure3 (Levetiracetam Tablets 4)

A bar graph comparing the percentage of patients between placebo and Levetiracetam 3000 mg/day groups. The x-axis shows treatment groups labeled Placebo (N=104) and Levetiracetam 3000 mg/day (N=180). The y-axis represents the percentage of patients from 0% to 45%, with Placebo around 14.4% and Levetiracetam at about 39.4%.*

FDA Label Image

Figure4 (Levetiracetam Tablets 5)

A bar graph comparing the percentage of patients between two groups: Placebo and Levetiracetam. The Placebo group (N=97) shows approximately 19.6% of patients, while the Levetiracetam group (N=101) shows approximately 44.6%. The graph includes a y-axis labeled as the percentage of patients, ranging from 0% to 45%.*

FDA Label Image

Figure5 (Levetiracetam Tablets 6)

A bar chart comparing the percentage of patients in two groups: Placebo (N=51) with 19.6% and Levetiracetam (N=58) with 43.1%. The chart's vertical axis represents the percentage of patients, ranging from 0% to 45%.*

FDA Label Image

Figure6 (Levetiracetam Tablets 7)

A bar chart comparing the percentage of patients between two groups: Placebo (N=84) and Levetiracetam (N=79). The Placebo group shows 45.2% of patients, while the Levetiracetam group shows 72.2%. The y-axis represents the percentage of patients from 0% to 100%.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.